Agenzia Italiana del Farmaco
Interactive OsMed Now Available - Updated with the Latest Data on Medicine Consumption and Expenditure in Italy - Interactive OsMed Now Available - Updated with the Latest Data on Medicine Consumption and Expenditure in Italy
Interactive OsMed Now Available - Updated with the Latest Data on Medicine Consumption and Expenditure in Italy

AIFA has launched the updated Interactive OsMed platform, providing online access to analyses from the latest edition of the National Report on Medicines Use in Italy (OsMed Report, 2023–2024, updated as of 26 April 2025). The platform enables users to perform customised queries on medicine use and expenditure indicators at national and regional levels, using dynamic tables, interactive charts, and multi-level comparison tools.
For years, the OsMed Report has been a key reference for analysing trends in pharmaceutical consumption and expenditure in Italy. Since 2020, AIFA has introduced an interactive online consultation mode, making the extensive data from the OsMed Report—available in print and digital formats—easier to navigate. This approach simplifies the extraction of relevant indicators for medicine use analysis, prescription appropriateness assessment, health planning, education and training, and institutional monitoring.
By accessing the dedicated page, users can explore datasets related to: approved healthcare assistance, medicine purchases by public health facilities, gross per capita expenditure, consumption by ATC classification and therapeutic category.
The platform also offers advanced comparative analysis tools, enabling users to compare indicators across regions and identify deviations from national averages. It includes time series data from 2018 onward, allowing multi-year trend analysis and regional comparisons to highlight differences and similarities in consumption and expenditure patterns.
Through Interactive OsMed, AIFA reinforces its role in supporting pharmaceutical governance by providing analytical tools that help identify critical areas, assess usage patterns, guide expenditure rationalisation measures, and ensure the sustainability of pharmaceutical assistance provided by the National Health Service.
Published on: 19 December 2025
